SCHEMBL2334273

SCHEMBL2334273

CS(=O)(=O)c1ccc(-n2cc(Cl)c(O)cc2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.47
PTGS2 P35354 14/20 0.43
PTGS1 P23219 3/20 0.42
ENPP2 Q13822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2524677 0.86 ALDH1A1 (0.39) GPR119PTGS2PTGS1
SCHEMBL2339014 0.82 HSD17B3 (0.43) GPR119PTGS2PTGS1ENPP2
SCHEMBL2329998 0.80 GPR119 (0.51) GPR119PTGS2
SCHEMBL2337239 0.79 GPR119 (0.45) GPR119PTGS2PTGS1ENPP2
SCHEMBL1550632 0.75 ENPP2 (0.50) GPR119PTGS2ENPP2
SCHEMBL10059432 0.70 KDM4E (0.61) PTGS2PTGS1
SCHEMBL12333865 0.70 GPR119 (0.58) GPR119PTGS2PTGS1
SCHEMBL2334277 0.70
SCHEMBL2336025 0.69 PTGS2 (0.45) GPR119PTGS2
SCHEMBL1577287 0.67 LMNA (0.55) PTGS2PTGS1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556069-B1 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-04-01 EP disclosed
EP-2556069-B1 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-04-01 EP disclosed
US-8513424-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-20 US disclosed
US-8415367-B2 Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 US disclosed
US-8415367-B2 Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 US disclosed
US-8415367-B2 Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 US disclosed
US-20120258959-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2012-10-11 US disclosed
US-8232404-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-31 US disclosed
WO-2011127106-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-13 WO disclosed
US-20110251221-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-10-13 US disclosed
US-20110251221-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-10-13 US disclosed
US-20110251221-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-10-13 US disclosed
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
EP-2170864-B1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-09-14 EP disclosed
US-8003796-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-23 US disclosed
EP-2170864-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-04-07 EP disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 US disclosed
WO-2009012275-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258959-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 GPR119 1/4885PTGS2 607/4885PTGS1 417/4885
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 GPR119 1/4885PTGS2 607/4885PTGS1 417/4885
US-20110251221-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR52 GPR119 1/4885PTGS2 722/4885PTGS1 556/4885
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 GPR119 1/4885PTGS2 626/4885PTGS1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.